Welcome to our dedicated page for Can-Fite BioPharma news (Ticker: CANF), a resource for investors and traders seeking the latest updates and insights on Can-Fite BioPharma stock.
Can-Fite BioPharma Ltd. reports developments for a clinical-stage biotechnology pipeline of proprietary small-molecule drugs targeting the A3 adenosine receptor (A3AR). Recurring news covers Namodenoson and Piclidenoson across oncology, inflammatory disease, liver disorders, metabolic disease, obesity-related uses, and companion-animal osteoarthritis through its veterinary commercialization relationship.
Company updates also include clinical and regulatory disclosures, patent allowances in multiple jurisdictions, operating and financial results, material agreements, capital-structure actions, and governance matters tied to its American Depositary Shares and ordinary-share voting processes.
Can-Fite (NYSE American: CANF) reported Phase 2a results for Namodenoson in advanced pancreatic ductal adenocarcinoma. The 20‑patient, open-label study met its primary safety endpoint, with Namodenoson well tolerated.
In eight evaluable third-line patients, median overall survival exceeded five months, with durable disease control and two patients still alive. One second-line patient remains alive beyond 18 months. Can-Fite plans a Phase 2b combination study with chemotherapy, supported by preclinical data showing Namodenoson enhances chemotherapeutic anti-tumor activity.
Can-Fite (NYSE American: CANF) received a Japanese patent allowance for Namodenoson's anti-obesity technology, covering A3 adenosine receptor agonists for fat loss, obesity, and related metabolic disorders.
The patent expands global IP protection alongside the US, Canada, Australia, and Israel, supporting partnering potential in an obesity therapeutics market forecast above $60 billion by 2030.
Can-Fite (NYSE American: CANF) announced a peer-reviewed Biomolecules Journal article highlighting the broad therapeutic potential of its A3 adenosine receptor agonists Piclidenoson and Namodenoson across oncology, inflammatory, metabolic, neurodegenerative, musculoskeletal and rare genetic diseases.
Namodenoson and Piclidenoson are in Phase 2–3 trials, supporting Can-Fite’s A3AR platform strategy.
Can-Fite (NYSE American: CANF) will present its late-stage clinical pipeline and licensing opportunities at the BIO International Convention 2026, held June 22–25 in San Diego.
The company plans partnering meetings focused on oncology, liver disease, inflammatory disease, and regional licensing for Namodenoson and Piclidenoson.
Can-Fite (NYSE American:TASE: CANF) reported encouraging clinical observations from its ongoing Phase 2a pancreatic cancer study of namodenoson. Enrollment is completed and several patients showed prolonged disease control, including one on therapy and follow-up for about 16 months. Namodenoson modulates RAS, Wnt/β-catenin and NF-κB pathways and, according to Can-Fite, has shown a favorable safety profile across clinical programs, aligning with growing interest in RAS pathway inhibition for pancreatic ductal adenocarcinoma.
Can-Fite (NYSE American: CANF) announced publication of a peer-reviewed article on Piclidenoson for canine osteoarthritis in Frontiers in Veterinary Science.
The study showed statistically significant improvements in mobility and pain with a favorable safety profile, supporting ongoing Phase 2 development and a Vetbiolix licensing deal potentially worth up to $325 million.
Can-Fite (NYSE American: CANF) plans a Phase 2b study of Namodenoson plus immunotherapy in advanced pancreatic cancer, following Phase 2a data showing a favorable safety profile, stable disease in >30% of evaluable patients, treatment beyond 16 months in a subset, and 35% remaining on therapy/follow-up.
Study design will be discussed at BIO International as Can-Fite advances partnership talks under confidentiality agreements.
Can-Fite (NYSE American: CANF) reported positive Phase 2a data for namodenoson in advanced pancreatic cancer on April 30, 2026. Key findings:
- Stable disease in >30% of evaluable patients
- 35% of patients remain on therapy, including one beyond 16 months
- Favorable safety and tolerability
Can-Fite (NYSE:CANF) announced that veterinary partner Vetbiolix completed enrollment in a randomized, double-blind, placebo-controlled Phase 2 study of piclidenoson in 118 dogs with osteoarthritis. The 90-day, twice-daily oral study uses LOAD as the primary endpoint; top-line results are expected in Q3 2026.
Vetbiolix exercised its option to a full license and will fund development and regulatory activities; Can-Fite may receive upfront, milestone, and royalty payments totaling up to $325 million over the next decade, contingent on successful development and commercialization.
Can-Fite (NYSE American: CANF) reported 2025 results and clinical progress on March 26, 2026. Key clinical milestones include a Phase 2a pancreatic cancer study meeting its primary safety endpoint, a HCC patient alive and cancer-free >9 years after Namodenoson, and decompensated cirrhosis improvement leading to transplant.
2025 financials: revenues $0.41M (-40% YoY), R&D $6.69M (+16.3%), G&A $3.66M (+20.2%), net loss $9.83M. Company raised ~$4.3M from warrant exercises in March 2026.